CollaGenex Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration has approved two phase 3 clinical trials of Col-101, a once-daily, modified-released formulation of doxycycline, 40 mg, for treatment of rosacea.
Insights into Bimekizumab 2-Year Data for PsA, nr-asSpA, and AS
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Deep Histological Margins Do Not Increase cSCC Recurrence Risk if Tumor is Fully Excised
The Cutaneous Connection: Enhancing Vitiligo Care With Nanette Silverberg, MD
Latex Gloves and the Americans With Disabilities Act
Live From Chicago: Bringing Sun Protection Awareness to Communities